In a report issued on February 13, Berenberg Bank from Berenberg Bank maintained a Buy rating on Zebra Tech (ZBRA – Research Report), with a price target of $660.00. The company’s shares closed last Monday at $426.42, close to its 52-week low of $423.54.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zebra Tech with a $575.00 average price target, which is a 30.0% upside from current levels. In a report issued on February 10, Needham also reiterated a Buy rating on the stock with a $580.00 price target.
Zebra Tech’s market cap is currently $22.63B and has a P/E ratio of 27.46.
Based on the recent corporate insider activity of 104 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZBRA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zebra Technologies Corp. engages in designing, manufacturing and selling of automatic identification and data capture products. Its products include mobile computers, barcode scanners, radio frequency identification devices (RFID) readers, specialty printers for barcode labeling and personal identification, real-time location systems, accessories and supplies, such as self-adhesive labels and other consumables, and software utilities and applications. It also provides services such as maintenance, technical support, repair, managed and professional services, including cloud-based subscriptions. It operates through the following two segments: Asset Intelligence & Tracking (AIT) and Enterprise Visibility & Mobility (EVM). The AIT segment comprises of barcode and card printing, location solutions, supplies, and services. The EVM segment comprises of mobile computing, data capture, and RFID. The company was founded by Edward L. Kaplan and Gerhard Cless in 1969 and is headquartered in Lincolnshire, IL.
Read More on ZBRA:
- Leerink Partners Thinks Hookipa Pharma’s Stock is Going to Recover
- Leerink Partners Keeps Their Buy Rating on Compass Therapeutics (CMPX)
- Viracta Therapeutics (VIRX) Receives a Buy from Leerink Partners
- Leerink Partners Thinks Elevation Oncology’s Stock is Going to Recover
- Tango Therapeutics (TNGX) Gets a Buy Rating from Leerink Partners